COVID-19: w gruncie rzeczy choroba śródbłonka

Peter Libby, Thomas Lüscher. COVID-19 is, in the end, an endothelial disease. Eur Heart J 2020;41: 3038–3044 (dostępny pełen tekst)

In view of the central role of inflammatory mediators in the complications of COVID-19, anti-inflammatory therapies merit careful clinical evaluation. Glucocorticoids and colchicine exert generalized anti-inflammatory actions and show promise in the treatment of patients with advanced COVID-19. Statins have direct anti-inflammatory effects beyond their lipid-lowering actions, mediated by inhibition of prenylation of small G proteins or induction of transcription factors such as KLF-2 that promote homeostatic endothelial functions. Non-randomized treatment with statins yielded preliminary retrospective evidence of improved outcomes in COVID-19, as well as reductions in biomarkers of inflammation …

Targeted inhibition of cytokines, major effectors of endothelial activation, represents a more focused approach than generalized anti-inflammatory agents …

European Heart Journal, 21 sierpnia 2020

Dodaj komentarz